The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra

Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24:751–73. Bobinac A, Van Exel J, Rutten F, Brouwer W. Caring for and caring about: disentangling the caregiving effect and the family effect. J Health Econ. 2010;29(4):549–56. Bobinac A, Van Exel J, Rutten F, Brouwer W. Health effects in significant others: separating family and caregiving effects. Med Decis Mak. 2011;31(2):292–8. Brouwer WBF, Tilford M, van Exel NJA. Incorporating caregiver and family effects in economic evaluations of child health. In: Ungar W, editor. Economic evaluation in child health. Oxford: Oxford Press; 2009. Hoefman RJ, van Exel NJA, Brouwer WBF. How to include informal care in economic evaluations. Pharmacoeconomics. 2013;31(12):1105–19. Al-Janabi H, van Exel NJA, Brouwer WBF, Trotter C, Glennie L, Hannigan L, et al. QALY losses in patients’ family networks: a study of the wider health effects of meningitis. Health Econ. 2016;25(12):1529–44. Al Janabi H, van Exel NJA, Brouwer WBF, Coast J. A framework for including health spillovers in economic evaluation. Med Decis Mak. 2016;36(2):176–86. Boadway R, Bruce N. Welfare economics. Oxford: Basil Blackwell; 1984. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer A. Discounting and decision-making in the economic evaluation of healthcare technologies. Health Econ. 2011;20:2–15. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. Grewal I, Lewis J, Flynn T, Brown J, Bond J, Coast J. Developing attributes for a generic quality of life measure for older people: preferences or capabilities? Soc Sci Med. 2006;62:1891–901. Netten A, Burge P, Malley J, Potoglou D, Towers A, Brazier J, et al. Outcomes of social care for adults: developing a preference-weighted measure. Health Technol Assess. 2012;16(16):1–165. Do YK, Norton EC, Steams SC, Van Houtven CH. Informal care and caregiver’s health. Health Econ. 2015;24(2):224–37. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the Caregiver Health Effects Study. JAMA. 1999;282(23):2215–9. Hoefman RJ, van Exel NJA, Brouwer WBF. Measuring the experienced impact of informal care on carers: a construct validation study of the CarerQol instrument in a large sample of caregivers. Health Qual Life Outcomes. 2013;11:173. Wittenberg E, Ritter GA, Prosser LA. Evidence of spillover of illness among household members: EQ-5D scores from a US sample. Med Decis Mak. 2013;33(2):235–43. Wittenberg E, Prosser LA. Disutility of illness for caregivers and families: a systematic review of the literature. Pharmacoeconomics. 2013;31(6):489–500. NICE. Guide to the methods of technology appraisal. London: NICE; 2013. Hoefman RJ, van Exel NJA, Brouwer WBF. How to include informal care in economic evaluations. Pharmacoeconomics. 2013;31(12):1105–19. Payakachat N, Tilford JM, Brouwer WBF, van Exel NJA, Grosse SD. Measuring health and well-being effects in family caregivers of children with craniofacial malformations. Qual Life Res. 2011;20(9):1487–95. Krol M, Papenburg J, van Exel NJA. Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies. Pharmacoeconomics. 2015;33(2):123–35. Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. Pharmacoeconomics. 2012;30(11):981–9. van Baal PHM, Meltzer D, Brouwer WBF. Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et al. Pharmacoeconomics. 2013;31(5):369–73. Barrett A, Roques T, Small M, Smith RD. How much will Herceptin really cost? BMJ. 2006;333(7578):1118–20. Tilford JM, Payakachat N. Progress in measuring family spillover effects for economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):195–8. McCabe C. Expanding the scope of costs and benefits for economic evaluations in health: some words of caution. Pharmacoeconomics. 2018. https://doi.org/10.1007/s40273-018-0712-8.